BMS-470539

a selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice; structure in first source

Also Known As:

Networked: 5 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tang, Jiping: 3 articles (01/2022 - 01/2020)
2.	Zhang, John H: 3 articles (01/2022 - 01/2020)
3.	Doycheva, Desislava Met: 2 articles (01/2022 - 01/2021)
4.	Gamdzyk, Marcin: 2 articles (01/2022 - 01/2021)
5.	Yu, Shufeng: 2 articles (01/2022 - 01/2021)
6.	Chen, Wen-Xiong: 1 article (01/2022)
7.	Gao, Yuanyuan: 1 article (01/2022)
8.	Guo, Yong: 1 article (01/2022)
9.	Travis, Zackary D: 1 article (01/2022)
10.	Lenahan, Cameron: 1 article (01/2021)

Related Diseases

1.	Neuroinflammatory Diseases 01/19/2021 - "Our study demonstrated that activation of MC1R with BMS-470539 attenuated neuroinflammation, and improved neurological deficits after neonatal hypoxic-ischemic brain injury in rats. " 01/19/2021 - "Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP/PKA/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats." 01/01/2020 - "The hypothesis of this study was that activation of melanocortin 1 receptor (MC1R) with BMS-470539 attenuates EBI by suppression of neuroinflammation after SAH. "
2.	Acute Lung Injury 05/01/2019 - "BMS-470539 improved lipopolysaccharide-induced acute lung injury and mortality in mice by affecting the inflammatory response." 05/01/2019 - "This study evaluated the effects of BMS-470539 on lipopolysaccharide-induced acute lung injury in a mouse model. " 05/01/2019 - "The effects of BMS-470539 on lipopolysaccharide-induced acute lung injury."
3.	Brain Injuries (Brain Injury) 01/19/2021 - "Our study demonstrated that activation of MC1R with BMS-470539 attenuated neuroinflammation, and improved neurological deficits after neonatal hypoxic-ischemic brain injury in rats. " 01/19/2021 - "Activation of MC1R with BMS-470539 attenuates neuroinflammation via cAMP/PKA/Nurr1 pathway after neonatal hypoxic-ischemic brain injury in rats."
4.	Infarction (Infarctions) 01/01/2022 - "BMS-470539 administration significantly attenuated short-term neurological deficits and infarct area, accompanied by a reduction in cleaved caspase-3-positive neurons at 48 h post-HI. " 01/19/2021 - "Activation of MC1R with BMS-470539 significantly reduced the percent infarct area, brain atrophy, and inflammation, and improved short- and long-term neurological deficits at 48 h and 28 days post-HI. "
5.	Sepsis (Septicemia) 05/01/2019 - "BMS-470539 improved sepsis-induced pulmonary edema, as demonstrated by a decreased W/D ratio (5.76%±0.83% to 3.81%±0.86%, P<0.05). "

Related Drugs and Biologics

1.	Lipopolysaccharides
2.	Type 1 Melanocortin Receptor
3.	NF-kappa B (NF-kB)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)